肾移植与隐球菌感染

肾移植是目前开展最广泛的器官移植项目,由于免疫抑制剂及糖皮质激素的大量使用,肾移植术后的真菌感染已经成为一个重要医学课题。隐球菌病是器官移植患者常见的深部真菌感染,本文对肾移植术后发生隐球菌感染的易感因素、临床表现以及治疗和预防等方面做一论述。     

肾移植术后隐球菌性脑膜炎的临床分析

目的 分析肾移植术后隐球菌性脑膜炎的临床特点,以期提高临床医生的诊治水平.方法 回顾性分析肾移植术后隐球菌性脑膜炎的临床表现、实验室检查和治疗预后.结果 4例患者中,男2例,女2例,全部为首次同种异体肾移植.所有患者均有发热和头痛症状,多表现为轻度头痛和低热.3例患者隐球菌涂片和培养均为阳性.所有患者分别给予两性霉素B脂质体、伏立康唑、5-氟胞嘧啶等抗真菌治疗,其中1例合并两性霉素B鞘内注射.经2～4个月治疗后,4例隐球菌涂片转阴,临床症状消失,均在我院随访,至今未复发.结论 肾移植术后隐球菌性脑膜炎首发症状隐匿,临床表现不典型,极易误诊漏诊.早期明确诊断、多科室协作、规范足量治疗是提高此病救治成功的关键.     

自然环境中新型隐球菌的调查

新型隐球菌能引起人类严重感染,甚至死亡的隐球菌病,发病率呈逐年上升趋势。所以研究它在自然环境中的存在状态,地理分布,复杂的生活史和传播途径,对及时有效地预防和控制隐球真菌病的发生和传播有着重要意义。     

艾滋病合并新生隐球菌感染的研究进展

新生隐球菌感染是全世界艾滋病患者死亡的主要原因,尤其是在撒哈拉以南非洲地区发病率最高[1]。新生隐球菌除了容易感染HIV个体外,还易感染其他免疫功能低下的个体,如造血系统恶性肿瘤、器官移植后服用免疫抑制剂及免疫缺陷病患者。格特隐球菌主要侵犯免疫功能正常的个体,但也感染免疫功能低下患者如合并艾滋病毒的患者[2]。     

2000～2008年原发性皮肤隐球菌病回顾性分析

目的了解2000～2008年间原发性皮肤隐球菌病(PCC)的流行病学及临床特征。方法检索并回顾性分析2000～2008年文献报道的原发性皮肤隐球菌病病例资料,对比分析2000～2008年与1985～2000年报道的PCC病例及免疫正常与免疫受损PCC病例的特征是否存在差异。结果共检索出2000～2008年间符合PCC诊断标准的病例28例。近8a来PCC仍好发于年龄较大者,但男性更多见;免疫正常或受损宿主均可发生PCC;HIV感染患者发生PCC几率更小;外伤可能为PCC重要的诱发因素;皮疹部位仍以四肢等暴露部位为主;皮疹性质由以前较特异的化脓性指头炎或蜂窝织炎为主变迁到以溃疡、结节、红斑、肿块等非特异性皮疹为主;治疗仍以抗真菌药物口服或与手术联合为主,氟康唑仍为一线药物;预后一般较好。结论近年来PCC表现出一些新的特点。宿主的免疫状态可能不影响其发生PCC的机率或影响较小,而仅影响隐球菌感染后的转归。     

伏立康唑治疗隐球菌病的研究进展

伏立康唑是新型的三唑类抗真菌药,现对隐球菌体外药敏试验、动物实验以及治疗隐球菌病的临床应用作一综述.     

原发性皮肤隐球菌病

原发性皮肤隐球菌病的存在与否多年来一直存在争议,直到近3年才逐步得到了确立。目前对于本病的研究刚刚开始。本文从本病的病原学、易感因素、临床表现、诊断、治疗以及皮肤感染后的全身播散等方面对本病作一介绍。     

肺隐球菌病12例临床分析

目的 提高对隐球菌病的认识.方法 对确诊为肺隐球菌病的12例病例的临床资料进行回顾性分析.结果 12例病例中,男性8例,女性4例,年龄31～68岁,平均年龄(51.8±12.6)岁,6例伴有基础疾病,但无1例有鸟类接触史;有临床症状者10例,其中咳嗽8例,咯痰3例,胸痛4例,发热2例,有体征者仅2例;胸部影像表现为:1...     

隐球菌病的诊治进展

隐球菌通常感染免疫功能低下的患者,荚膜多糖是其主要的致病因子,隐球菌主要通过肺进入机体从而引起肺隐球菌病,但因其嗜神经的特性,中枢神经系统也是隐球菌的主要靶器官。隐球菌感染的主要危险因素包括H IV感染和器官移植。由于感染部位的不同和患者的免疫功能的差异,其临床症状也多种多样,轻者无症状,重者危及生命。治疗方案主要由患者的免疫状态和病情的严重程度决定,主要包括多烯类和咪唑类抗真菌药物的治疗。即使经过抗真菌治疗,H IV患者隐球菌病的病死率仍较高,而CME(隐球菌性脑膜炎/脑膜脑炎)患者的临床治疗失败率之高让人难以接受。现介绍近年来隐球菌病在诊断和治疗方面的进展,并对未来治疗的发展趋势作简要的评价。     

播散性隐球菌病1例

我们在临床工作中遇到1例播散性隐球菌病患者，现报道如下。     

55例社区获得性肺隐球菌病病例分析

本文旨在通过研究社区获得性肺隐球菌病的临床特点,提高医务人员对肺隐球菌病的认识,做到早期诊断和治疗.采用回顾性病例分析研究,统计2003年1月~2009年12月入住复旦大学附属中山医院的55例确诊及临床诊断为肺隐球菌病患者的临床资料.55例患者中,男性34例,女性21例;年龄17~75岁,平均(44.8±13.4)岁....     

Cryptococcus neoformans varieties as agents of cryptococcosis in Brazil

The study of the clinical isolates of Cryptococcus neoformans from 83 Brazilian patients with disseminated cryptococcosis showed that 75 were C. neoformans var. neoformans and 8 were var. gattii. Twenty-seven isolates were serotyped; all 19 var. neoformans were serotype A and all 8 var. gattii were serotype B. The correlation of the varieties of C. neoformans with the presence or not of hosts predisposing conditions to the mycosis showed that: (1) cryptococcosis caused by gattii variety occurred in 7 (58.3%) of the 12 nonimmunosuppressed patients, and (2) cryptococcosis caused by neoformans variety occurred in 65 (98.5%) of the 66 AIDS patients and in all 5 patients with other immunosuppressive conditions. The comparison of the distribution of the gattii and neoformans varieties between the nonimmunosup-pressed and immunosuppressed patients showed a significant statistical difference (p < 0.01).     

以反复多发脓肿为表现的播散型隐球菌病1例

报道以反复多发脓肿为表现的播散型隐球菌病患者1例。患者男,68岁,因＂全身反复多发性脓肿1a,伴低热2个月余＂入院,该患者以背部脓肿起病,反复发作累及肺部、骨骼、皮肤等多部位,多次组织及血标本病原学检查、隐球菌乳胶凝集试验均阴性,给予多种抗菌药物治疗无效,后在右髂部脓肿切开组织物中培养到新生隐球菌。经脓肿切开引流及静脉滴注两性霉素B脂质体联合伊曲康唑治疗后,脓肿消退,症状消失,改用氟康唑联合氟胞嘧啶治疗4个月后停药,并已随访至今7个月,患者未有发热及新的脓肿出现。     

播散性隐球菌病1例及其实验研究

目的 播散性隐球菌病1例临床及实验研究.方法 患者男,72岁,红皮病1年2个月,口服醋酸泼尼松治疗,双下肢出现结节、溃烂6个月.皮损组织病理、皮损组织真菌培养、尿素酶试验、PCR扩增测序比对明确诊断,同时做胸部及脑部CT.结果 皮损组织病理显示为感染肉芽肿改变,可见大量圆形和椭圆形酵母细胞.皮损组织真菌培养可见酵母样菌落生长,菌株尿素酶试验阳性,ITS区测序比对鉴定为新生隐球菌grubii变种.血清隐球菌荚膜多糖抗原乳胶凝集试验阳性(++++).胸部CT显示左下肺后基底段空洞性病灶.依据临床及实验室检查确诊为由新生隐球菌grubii变种引起的 播散性隐球菌病.给予患者静滴氟康唑400 mg/d治疗2周,之后改口服300 mg/d治疗,3个月后结节性皮损全部消退,胸片显示左肺陈旧性病变,血清隐球菌荚膜多糖抗原乳胶凝集试验阳性(++).治疗15个月后,血清隐球菌荚膜多糖抗原乳胶凝集试验仍阳性(++).结论 对该病例的临床和实验室研究为临床明确诊断和治疗提供了依据,确定菌种需要进行分子生物学研究.     

Molecular analysis of 311 Cryptococcus neoformans isolates from a 30-month ECMM survey of cryptococcosis in Europe

During a European Confederation of Medical Mycology (ECMM) prospective survey of cryptococcosis in Europe (from July 1997 to December 1999) 655 cases were reported from 17 countries; 565 of the completed questionnaires were evaluable. Cryptococcosis was associated with HIV infection in 77% of cases (range 57.5-94%). Assessment of the laboratory data highlighted the lack of defined standard procedures for the diagnosis of cryptococcosis: the antigen test was not usually used for screening, the disease was mainly recognised when meningitis occurred (65% of patients) and, with the exception of a few cases, the extent of the infection was not investigated. Cryptococcus neoformans was the etiological agent in all of the cases except for six caused by C. gattii and four by other Cryptococcus species. A total of 311 C. neoformans strains were serotyped by Crypto Check latex agglutination, genotyped by PCR-fingerprinting using the (GACA)4 oligonucleotide as a single primer, and their mating type was determined by PCR of the STE20 alleles. Serotype A was the most represented (51% of the isolates), followed by serotype D (30%) and serotype AD (19%). PCR-fingerprinting analysis significantly increased the percentage of hybrid strains to 30%, as 6% of the serotype A and 28% of the serotype D isolates were of the VN3 or VN4 hybrid genotype. In addition, the mating type determinations revealed the MATa serotype A allele in one haploid strain and 28 hybrids, and hybrid isolates with a single mating type (four Aalpha and two Dalpha) were also identified. This is the first prospective survey to be carried out in Europe which has attempted to investigate the epidemiology of cryptococcosis and the population structure of C. neoformans, and the results obtained thus far show the widespread involvement of AD hybrid strains in C. neoformans infections.     

Cryptococcosis in Colombian children and literature review

Cryptococcosis is reported in adults and is often acquired immune deficiency syndrome (AIDS)-associated; however, its frequency in children is low. Based on the National Survey on Cryptococcosis conducted in Colombia, an epidemiological and clinical analysis was performed on cases of the disease observed in children less than 16 years old between 1993-2010. We found 41 affected children (2.6% prevalence) from the 1,578 surveys received. The country mean annual incidence rate was 0.017 cases/100,000 children under 16 years, while in Norte de Santander the incidence rate was 0.122 cases/100,000 (p < 0.0001). The average age of infected children was 8.4 and 58.5% were male. In 46.3% of cases, a risk factor was not identified, while 24.4% had AIDS. The most frequent clinical manifestations were headache (78.1%), fever (68.8%), nausea and vomiting (65.6%), confusion (50%) and meningeal signs (37.5%). Meningitis was the most frequent clinical presentation (87.8%). Amphotericin B was given to 93.5% of patients as an initial treatment. Positive microbiological identification was accomplished by India ink (94.7%), latex in cerebrospinal fluid (100%) and culture (89.5%). Out of 34 isolates studied, Cryptococcus neoformans var. grubii (VNI 85.3%, VNII 8.8%) was isolated in 94.1% of cases and Cryptococcus gattii (VGII) was isolated in 5.9% of cases. These data are complemented by a literature review, which overall suggests that cryptococcosis in children is an unusual event worldwide.     

Genotype and mating type analysis of Cryptococcus neoformans and Cryptococcus gattii isolates from China that mainly originated from non-HIV-infected patients

Cryptococcosis has been reported to be mostly associated with non-HIV-related patients in China. However, little is known about the molecular characteristics of clinical isolates from the Cryptococcus neoformans species complex in this country. In this study, 115 clinical isolates were included. Molecular type VNI was the most representative ( n =103), followed by VGI ( n =8), VNIII ( n =2), VNIV ( n =1), and VGII ( n =1). With the exception of a serotype D mating type a isolate, all possessed the MAT α locus. Multilocus sequence typing (MLST) revealed that most Cryptococcus gattii isolates from China shared identical MLST profiles with the most common MLST genotype reported in the VGI group, and the only one VGII isolate resembled the Vancouver Island outbreak minor genotype. The C. gattii strains involved in this study were successfully grouped according to their molecular type and mating types by PCR-restriction fragment length polymorphism (RFLP) analysis of the GEF1 gene. Our results suggest that (1) in China, cryptococcosis is mostly caused by C. neoformans var. grubii (molecular type VNI), and mating type α; (2) The most common causative agents of C. gattii infection in China are closely related to a widely distributed MLST genotype; and (3) The PCR-RFLP analysis of the GEF1 gene has the potential to identify the molecular and mating types of C. gattii simultaneously.     

Serum uromodulin predicts graft failure in renal transplant recipients

Objective and methods: Test the ability of serum uromodulin concentrations 1–3 months after renal transplantation to predict all-cause mortality (ACM) and graft loss (GL) in 91 patients.

Results: uromodulin predicted GL equivalently to the other markers studied: the risk for GL was reduced by 0.21 per one standard deviation (SD) increase (cystatin C: hazard ratio [HR] 4.57, creatinine: HR 4.53, blood-urea-nitrogen [BUN]: HR 2.50, estimated glomerular filtration rate [eGFR]: HR 0.10). In receiver-operating-characteristic (ROC) analysis, uromodulin predicted GL with an area-under-the curve of 0.782 at an optimal cut-off (OCO) of 24.0?ng/ml with a sensitivity of 90.0% and a specificity of 70.2%.

Conclusion: Serum uromodulin predicted GL equivalently compared to conventional biomarkers of glomerular filtration.     

Nanomedicines in renal transplant rejection--focus on sirolimus

Nanomedicine, known as the application of nanotechnology in medicine, has been applied to overcome the problems of poor bioavailability, in vitro and in vivo stability, and targeted delivery in the preparation of pharmaceutical products. Sirolimus, a water-insoluble immunosuppressant, has been formulated into an oral solid dosage form by using NanoCrystal technology to increase the water solubility and thereby the bioavailability. The efficacy, safety, and pharmacokinetic properties are not significantly different between liquid and solid formulations except that less fluctuation of sirolimus blood concentration was observed in solid dosage form. The tablet formulation offers the advantages of better palatability and more convenience for long-term use. Sirolimus tablets are not only a successful example of nanomedicine, but also a more cost-effective treatment in renal transplantation than cyclosporine and tacrolimus.